Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$3.99
+7.5%
$3.18
$0.93
$4.08
$1.05B0.883.17 million shs4.71 million shs
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
$14.37
+3.0%
$14.94
$8.24
$18.38
$936.64M-0.3552,013 shs596,239 shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$16.55
+6.0%
$15.41
$10.91
$40.26
$997.63M2.68580,609 shs566,300 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$2.54
+5.8%
$0.53
$0.13
$3.29
$317.40M2.044.61 million shs18.84 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
+2.20%+3.92%-6.55%+118.24%+291.35%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
+3.10%+1.82%-13.46%+8.73%+11.16%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
+2.03%+0.77%-8.01%+16.75%-41.01%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-10.11%+67.83%+972.39%+315.22%+164.87%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4.2316 of 5 stars
3.64.00.04.02.00.80.6
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2.1521 of 5 stars
3.41.00.00.01.44.20.0
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
1.3425 of 5 stars
3.60.00.00.00.01.70.6
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
3.9437 of 5 stars
4.35.00.00.02.81.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.20
Buy$6.7569.17% Upside
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2.75
Moderate Buy$32.25124.43% Upside
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
3.25
Buy$53.40222.66% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.60
Moderate Buy$5.63121.60% Upside

Current Analyst Ratings Breakdown

Latest VOR, AKBA, SYRE, and MLYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$3.00
6/26/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Outperform
6/17/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00
6/10/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$15.00
6/4/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
5/14/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$48.00
5/13/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
5/9/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/9/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Perform$6.00 ➝ $6.00
5/9/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
5/8/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$184.91M5.67N/AN/A($0.23) per share-17.35
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/A$3.84 per shareN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$890K1,120.94N/AN/A$7.04 per share2.35
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$69.41M-$0.21N/AN/AN/A-24.51%N/A-18.92%8/6/2025 (Estimated)
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$177.81M-$3.73N/AN/AN/AN/A-71.15%-65.71%8/12/2025 (Estimated)
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$208.02M-$3.77N/AN/AN/AN/A-77.46%-41.06%8/6/2025 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/A-$1.51N/AN/AN/AN/AN/AN/AN/A

Latest VOR, AKBA, SYRE, and MLYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.68N/AN/AN/AN/AN/A
5/12/2025Q1 2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$1.02-$0.79+$0.23-$0.79N/AN/A
5/8/2025Q1 2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million
5/8/2025Q1 2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.76-$0.74+$0.02-$0.74N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
1.89
2.23
2.02
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/A
26.48
26.48
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/A
8.06
8.06
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
84.46%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
80.39%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.00%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
33.24%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
6.20%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
430262.64 million254.76 millionOptionable
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2865.18 million43.51 millionOptionable
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
7360.28 million56.54 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
140124.96 million65.45 millionNot Optionable

Recent News About These Companies

Biopharma layoffs for first half of the year jump 32% YOY
Analysts Set Vor Biopharma Inc. (NYSE:VOR) Price Target at $5.63
HC Wainwright Predicts Weaker Earnings for Vor Biopharma
HC Wainwright Upgrades Vor Biopharma (NYSE:VOR) to "Buy"
Vor Biopharma (NYSE:VOR) Upgraded at HC Wainwright
Vor Biopharma (NYSE:VOR) Gains Momentum S&P 500
Vor Biopharma Inc. Stock Grades - Barron's

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$3.99 +0.28 (+7.55%)
Closing price 04:00 PM Eastern
Extended Trading
$4.01 +0.02 (+0.50%)
As of 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Mineralys Therapeutics stock logo

Mineralys Therapeutics NASDAQ:MLYS

$14.37 +0.42 (+3.01%)
Closing price 04:00 PM Eastern
Extended Trading
$14.36 0.00 (-0.03%)
As of 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Spyre Therapeutics stock logo

Spyre Therapeutics NASDAQ:SYRE

$16.55 +0.94 (+6.02%)
Closing price 04:00 PM Eastern
Extended Trading
$16.28 -0.27 (-1.60%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Vor Biopharma stock logo

Vor Biopharma NYSE:VOR

$2.54 +0.14 (+5.83%)
Closing price 04:00 PM Eastern
Extended Trading
$2.60 +0.06 (+2.56%)
As of 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.